A pilot study of recombinant human interleukin-4 therapy of myelofibrosis

Francis J. Giles*, Anna R. Keating, Razelle Kurzrock, Moshe Talpaz

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Twelve patients with myelofibrosis were treated with recombinant human interleukin-4 (IL-4) administered subcutaneously thrice weekly. Dosage ranged from 1 μg/kg to 4 μg/kg. Median patient age was 65 years (range 36-74). Five patients had transient minor responses, and 5 patients had progressive disease. One patient had a transient minor response, rapidly followed by progressive disease. One patient suffered angioneurotic edema with first injection. Other significant toxicities included fever, flu-like symptoms, peripheral edema, and ascites. IL-4 at this schedule was toxic and had no significant activity in myelofibrosis.

Original languageEnglish (US)
Pages (from-to)1253-1255
Number of pages3
JournalJournal of Interferon and Cytokine Research
Issue number11
StatePublished - 1999

ASJC Scopus subject areas

  • Virology
  • Cell Biology
  • Immunology


Dive into the research topics of 'A pilot study of recombinant human interleukin-4 therapy of myelofibrosis'. Together they form a unique fingerprint.

Cite this